| | | | | | | | | | | | | | | | |
| |
![Collapse](/DXR.axd?r=1_87-p7f1t) | Issue Date FY: 2024 ( Subtotal = $214,692,622 ) (Continued on the next page) |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI178284 | Role of local antibodies in control of chronic genital herpes | 000 | 1 | NIH | 2/5/2024 | $800,540 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | K99CA277552 | Assessing how multilevel factors shape disparities in cancer screening | 001 | 2 | NIH | 4/30/2024 | $209,250 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA227092 | Novel Intervention Approaches to Alleviate Allogeneic Transplant-Related Morbidity and Mortality | 001 | 6 | NIH | 4/17/2024 | $42,607 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA227092 | Novel Intervention Approaches to Alleviate Allogeneic Transplant-Related Morbidity and Mortality | 000 | 6 | NIH | 1/30/2024 | $766,928 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI136946 | Mechanisms and consequence of helical shape generation in Helicobacter pylori | 001 | 7 | NIH | 3/27/2024 | $559,231 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35GM124593 | Cellular mechanisms governing nutrient sensing and organismal energy homeostasis | 000 | 8 | NIH | 7/17/2024 | $68,423 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA231838 | Immunogenetics of Outcomes Disparities After Allogeneic HCT | 000 | 8 | NIH | 4/4/2024 | $424,151 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U01HG013177 | Statistical Methods for Inferring Gene-Phenotype Associations Using Omic Data from Gene Knockout and Human Phenotype Studies | 000 | 2 | NIH | 7/22/2024 | $551,900 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01MD017599 | Health and Financial Costs of Unequal Care: Colorectal Cancer as a Case Study | 002 | 2 | NIH | 3/22/2024 | $414,073 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01MD017599 | Health and Financial Costs of Unequal Care: Colorectal Cancer as a Case Study | 003 | 2 | NIH | 5/28/2024 | $32,205 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R13OD024033 | Annual HVTN Translational HIV Early Stage Investigator (ESI) Conference | 001 | 8 | NIH | 5/9/2024 | $14,999 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R13OD024033 | Annual HVTN Translational HIV Early Stage Investigator (ESI) Conference | 000 | 8 | NIH | 3/29/2024 | $60,000 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AR070780 | Differentiation balances oncogene-driven proliferation to maintain epidermal homeostasis | 000 | 8 | NIH | 6/6/2024 | $588,572 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI146028 | Blending deep learning with probabilistic mechanistic models to predict and understand the evolution and function of adaptive immune receptors | 000 | 6 | NIH | 5/31/2024 | $689,648 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35GM119835 | Regulation of Protein Synthesis by Synonymous Codon Usage | 000 | 10 | NIH | 5/8/2024 | $425,872 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35GM119774 | Real-time tracking of virus evolution for vaccine strain selection and epidemiological investigation | 000 | 10 | NIH | 5/9/2024 | $418,074 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01HL130483 | Statistical methods for analyzing objectively measured physical activity. | 000 | 9 | NIH | 6/14/2024 | $442,452 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | K25AI155224 | Simulating persistence and elimination of the HIV reservoir | 000 | 6 | NIH | 7/16/2024 | $123,030 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35GM118120 | Molecular analysis of genetic recombination and DNA break repair | 001 | 10 | NIH | 6/26/2024 | $97,108 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35GM118120 | Molecular analysis of genetic recombination and DNA break repair | 000 | 10 | NIH | 4/10/2024 | $873,974 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | T32AI118690 | Training Program in Infectious Diseases in the Immunocompromised Host | 000 | 10 | NIH | 5/30/2024 | $436,073 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI123323 | Inflammation-driven T Cell Responses and their Dichotomous Effect on Host Immunity | 000 | 9 | NIH | 7/1/2024 | $528,000 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI140891 | Complete mapping of immune selection from antibodies to HIV | 001 | 7 | NIH | 5/16/2024 | $40,271 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI140891 | Complete mapping of immune selection from antibodies to HIV | 000 | 7 | NIH | 12/14/2023 | $362,442 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01GM105785 | Statistical Methods for RNA-seq Data Analysis | 000 | 11 | NIH | 7/2/2024 | $437,166 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AR066248 | SMCHD1 Pathways as Candidate Targets for FSHD | 000 | 11 | NIH | 6/6/2024 | $417,286 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U10CA180819 | SWOG Statistics and Data Management Center | 002 | 11 | NIH | 4/17/2024 | $401,127 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U10CA180819 | SWOG Statistics and Data Management Center | 001 | 11 | NIH | 3/4/2024 | $7,220,289 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | SDMC: HIV Vaccine Trials Network | 005 | 19 | NIH | 4/18/2024 | $0 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | SDMC: HIV Vaccine Trials Network | 005 | 19 | NIH | 4/18/2024 | $0 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | SDMC: HIV Vaccine Trials Network | 004 | 19 | NIH | 4/4/2024 | $9,074,979 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | SDMC: HIV Vaccine Trials Network | 004 | 19 | NIH | 4/4/2024 | $6,921,264 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | SDMC: HIV Vaccine Trials Network | 001 | 19 | NIH | 11/16/2023 | $9,074,980 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | SDMC: HIV Vaccine Trials Network | 001 | 19 | NIH | 11/16/2023 | $6,921,265 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 009 | 19 | NIH | 3/21/2024 | $9,774,635 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 009 | 19 | NIH | 3/21/2024 | $699,895 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 009 | 19 | NIH | 3/21/2024 | $250,000 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 003 | 19 | NIH | 11/14/2023 | $9,774,636 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 003 | 19 | NIH | 11/14/2023 | $699,896 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 003 | 19 | NIH | 11/14/2023 | $250,000 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 003 | 19 | NIH | 11/14/2023 | $500,000 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 008 | 19 | NIH | 7/12/2024 | $0 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 008 | 19 | NIH | 7/12/2024 | $0 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 008 | 19 | NIH | 7/12/2024 | $0 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 007 | 19 | NIH | 3/20/2024 | $9,067,448 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 007 | 19 | NIH | 3/20/2024 | $6,336,305 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 000 | 19 | NIH | 11/8/2023 | $9,067,449 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 000 | 19 | NIH | 11/8/2023 | $3,836,305 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 000 | 19 | NIH | 11/8/2023 | $400,000 |
|